Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
35
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecainide,
encainide, flecainide, propafenone, quinidine. Thereby, increasing
propafenone, quinidine the risk of arrhythmias or other serious adverse
effects from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Ergot Derivatives Dihydroergotamine, Increased plasma concentrations of ergot
ergonovine, derivatives leading to acute ergot toxicity,
ergotamine, including vasospasm and ischaemia.
methylergonovine
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Thereby, increasing the risk of serious
arrhythmias from this agent.
Lipid-modifying agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Lurasidone Due to CYP3A inhibition by ritonavir, concentrations of lurasidone are expected to
increase. The concomitant administration with lurasidone is contraindicated (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Lurasidone Due to CYP3A inhibition by ritonavir, concentrations of lurasidone are expected to
increase. The concomitant administration with lurasidone is contraindicated (see section
4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 9a901670059096c3f491f539bb11730c25bd259aea37f3ebe13a675f7bc6cec8 · Zeichen 40083–40383 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.